Marwah Adly Saleh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marwah Adly Saleh has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
Masayuki Amagai
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
6 shared publications- Dedee Frances Murrell
Department of Dermatology, St George Hospital, Sydney, Australia
4 shared publications Noha Adly Saleh
Department of Dermatology Cairo University Cairo Egypt
4 shared publications- Enno Schmidt
Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
3 shared publications - Jun Yamagami
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
3 shared publications Laila Ahmed Rashed
Department of Biochemistry Faculty of Medicine Cairo University Cairo Egypt
3 shared publications
Latest Publications
- Open Access
- 11 December 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (2) , 100339
Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece
- 11 December 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (2) , 100339
Open AccessAdvances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece
- 13 November 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (3) , E111-E113
Postpartum Castleman disease presenting as paraneoplastic pemphigus: a case report
- 13 November 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (3) , E111-E113
Postpartum Castleman disease presenting as paraneoplastic pemphigus: a case report
- 2 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (11) , 6343-6350
Assessment of tissue E‐cadherin and its proteolytic serum fragment in pemphigus vulgaris before and after remission: A case–control study
Background: E‐cadherin is a classic cadherin that mediates keratinocyte adhesion.Aims: To assess the tissue expression of E‐cadherin and its proteolytic serum fragment (soluble E‐cadherin) in pemphigus vulgaris (PV) before and after clinical remission compared with controls.Patients: Thirty‐seven PV patients and thirty controls were enrolled. Pemphigus disease area index (PDAI) was calculated for patients at baseline and after remission. Punch biopsy specimens were taken from patients before, and after remission, and from controls for assessment of tissue E‐cadherin by immunofluorescence. Similarly, serum samples were collected for assessment of serum soluble E‐cadherin by ELISA.Results: Presence, intensity, and mean intensity of tissue E‐cadherin were significantly reduced in PV patients before treatment compared with controls (p < 0.001). Detected E‐cadherin showed mainly a basal and suprabasal distribution with cell surface and a cytoplasmic expression. Serum E‐cadherin was significantly higher in patients before treatment compared with controls (p = 0.006). With remission, tissue E‐cadherin presence, intensity, mean intensity, and serum E‐cadherin showed statistically significant improvement (p = 0.003, p = 0.49 and 0.44, respectively).Conclusions: Disruption of tissue E‐cadherin and upregulation of serum soluble E‐cadherin can contribute to the pathogenesis of PV. Clinical remission of PV is associated with normalization of tissue and serum E‐cadherin.
- 2 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (11) , 6343-6350
Assessment of tissue E‐cadherin and its proteolytic serum fragment in pemphigus vulgaris before and after remission: A case–control study
Background: E‐cadherin is a classic cadherin that mediates keratinocyte adhesion.Aims: To assess the tissue expression of E‐cadherin and its proteolytic serum fragment (soluble E‐cadherin) in pemphigus vulgaris (PV) before and after clinical remission compared with controls.Patients: Thirty‐seven PV patients and thirty controls were enrolled. Pemphigus disease area index (PDAI) was calculated for patients at baseline and after remission. Punch biopsy specimens were taken from patients before, and after remission, and from controls for assessment of tissue E‐cadherin by immunofluorescence. Similarly, serum samples were collected for assessment of serum soluble E‐cadherin by ELISA.Results: Presence, intensity, and mean intensity of tissue E‐cadherin were significantly reduced in PV patients before treatment compared with controls (p < 0.001). Detected E‐cadherin showed mainly a basal and suprabasal distribution with cell surface and a cytoplasmic expression. Serum E‐cadherin was significantly higher in patients before treatment compared with controls (p = 0.006). With remission, tissue E‐cadherin presence, intensity, mean intensity, and serum E‐cadherin showed statistically significant improvement (p = 0.003, p = 0.49 and 0.44, respectively).Conclusions: Disruption of tissue E‐cadherin and upregulation of serum soluble E‐cadherin can contribute to the pathogenesis of PV. Clinical remission of PV is associated with normalization of tissue and serum E‐cadherin.
- 5 May 2022
- Published by Wiley in Wound Repair and Regeneration
- Vol. 30 (4) , 448-452
Downregulation of aquaporin 3 in patients with pemphigus vulgaris
Pemphigus vulgaris (PV) is an autoimmune bullous skin disease. Aquaporin 3 (AQP3) is a glycerol/water channel involved in several physiological functions. Evaluation of the tissue expression and localization of AQP3 in the skin of PV patients. Twenty-seven PV patients and 30 controls were included. The patients were subjected to history taking, clinical evaluation, Autoimmune Bullous Skin Disorder Intensity Score and 4-mm punch biopsy. The biopsies were stained using anti-human AQP3 antibody and the immunofluorescence pattern and intensity were evaluated using a scoring system and ImageJ software analysis. AQP3 was expressed in the basal epidermis in 27 (100%) and in the suprabasal epidermis in 19 PV patients (70.4%). It was expressed in all controls in basal and suprabasal layers. Intensity of AQP3 immunofluorescence was strong in 2 (7.4%), moderate in 19 (70.4%) and weak in 6 patients (22.2%) while it was strong in 18 (60%) and moderate in 12 controls (40%). AQP3 expression was significantly lower in patients than controls in the suprabasal epidermis (p = 0.001). Patients with extensive disease had significantly weaker AQP3 intensity than those with marked disease (p = 0.005) Downregulation of AQP3 in patients with PV, especially in the suprabasal layers and in extensive clinical disease, suggests a potential role of AQP3 in the pathogenesis of PV.
- 5 May 2022
- Published by Wiley in Wound Repair and Regeneration
- Vol. 30 (4) , 448-452
Downregulation of aquaporin 3 in patients with pemphigus vulgaris
Pemphigus vulgaris (PV) is an autoimmune bullous skin disease. Aquaporin 3 (AQP3) is a glycerol/water channel involved in several physiological functions. Evaluation of the tissue expression and localization of AQP3 in the skin of PV patients. Twenty-seven PV patients and 30 controls were included. The patients were subjected to history taking, clinical evaluation, Autoimmune Bullous Skin Disorder Intensity Score and 4-mm punch biopsy. The biopsies were stained using anti-human AQP3 antibody and the immunofluorescence pattern and intensity were evaluated using a scoring system and ImageJ software analysis. AQP3 was expressed in the basal epidermis in 27 (100%) and in the suprabasal epidermis in 19 PV patients (70.4%). It was expressed in all controls in basal and suprabasal layers. Intensity of AQP3 immunofluorescence was strong in 2 (7.4%), moderate in 19 (70.4%) and weak in 6 patients (22.2%) while it was strong in 18 (60%) and moderate in 12 controls (40%). AQP3 expression was significantly lower in patients than controls in the suprabasal epidermis (p = 0.001). Patients with extensive disease had significantly weaker AQP3 intensity than those with marked disease (p = 0.005) Downregulation of AQP3 in patients with PV, especially in the suprabasal layers and in extensive clinical disease, suggests a potential role of AQP3 in the pathogenesis of PV.
- Open Access
- 12 April 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (4) , 100129
How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey
- 12 April 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (4) , 100129
Open AccessHow Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey
- Open Access
- 2 February 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (4) , e15354
Pemphigus vulgaris relapse during the coronavirus disease pandemic
Pemphigus vulgaris (PV) is the most common type of pemphigus group of autoimmune skin diseases. The treatment of PV relapse is challenging especially during the coronavirus disease (COVID-19) pandemic. In this prospective study, we aimed to evaluate the treatment of patients with relapsing PV during the pandemic. Twelve patients with PV who experienced relapse from March 2020 to January 2022 were included. The patients were asked whether they experienced COVID-19 symptoms and the pemphigus disease area index (PDAI) was measured. PCR for COVID-19, chest computed tomography, routine investigations, and electrocardiography were performed for the admitted patients. The mean PDAI of the patients during relapse was 23.6 ± 14.8 (range, 5–60). Seven patients received azathioprine; one patient received mycophenolate mofetil; and six patients received 1000 mg of rituximab (RTX) twice at an interval of 14 days. None of the 12 patients had COVID-19-suggestive symptoms. Only 1 patient relapsed after receiving the COVID-19 vaccine. The six admitted patients who received RTX were negative for COVID-19 based on the PCR testing results. Out of the 12 patients, eight achieved complete remission, while four achieved partial remission. No major adverse effects were observed. In conclusion, the treatments with systemic steroids, immunosuppressive drugs, and rituximab were well tolerated by the patients with relapsing PV, provided that there was no contact with individuals with COVID-19. These treatments can then be provided to patients with PV during the pandemic with careful follow-up.
- 2 February 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (4) , e15354
Open AccessPemphigus vulgaris relapse during the coronavirus disease pandemic
Pemphigus vulgaris (PV) is the most common type of pemphigus group of autoimmune skin diseases. The treatment of PV relapse is challenging especially during the coronavirus disease (COVID-19) pandemic. In this prospective study, we aimed to evaluate the treatment of patients with relapsing PV during the pandemic. Twelve patients with PV who experienced relapse from March 2020 to January 2022 were included. The patients were asked whether they experienced COVID-19 symptoms and the pemphigus disease area index (PDAI) was measured. PCR for COVID-19, chest computed tomography, routine investigations, and electrocardiography were performed for the admitted patients. The mean PDAI of the patients during relapse was 23.6 ± 14.8 (range, 5–60). Seven patients received azathioprine; one patient received mycophenolate mofetil; and six patients received 1000 mg of rituximab (RTX) twice at an interval of 14 days. None of the 12 patients had COVID-19-suggestive symptoms. Only 1 patient relapsed after receiving the COVID-19 vaccine. The six admitted patients who received RTX were negative for COVID-19 based on the PCR testing results. Out of the 12 patients, eight achieved complete remission, while four achieved partial remission. No major adverse effects were observed. In conclusion, the treatments with systemic steroids, immunosuppressive drugs, and rituximab were well tolerated by the patients with relapsing PV, provided that there was no contact with individuals with COVID-19. These treatments can then be provided to patients with PV during the pandemic with careful follow-up.
- 22 January 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (1) , 61-66
Comparison of vascular endothelial growth factor expression between lesional and non-lesional skin in patients with morphea: a dermoscopy-guided immunohistochemical study
Morphea is an inflammatory fibrosing disease, initiated by vascular injury resulting in increased collagen formation and decreased collagen degradation. This study was designed to evaluate the role of angiogenic vascular endothelial growth factor (VEGF) in the vascular changes which are dermoscopically evident in morphea lesions, compared with that in non-lesional skin, by assessing its expression immunohistochemically on tissue blood vessels. Twenty patients with morphea were subjected to clinical and dermoscopic examinations. Two skin biopsies from lesional and non-lesional skin were obtained and stained with hematoxylin and eosin (H&E) and immunohistochemically with VEGF. Dermoscopic examination showed linear blood vessels in 90% of the lesions. No significant difference in the number of VEGF-stained and unstained blood vessels, was observed between the lesional and non-lesional skin (p = 0.475 and 0.191, respectively). A weak inverse correlation was found between the total number of blood vessels positive for VEGF and the disease duration, (r = − 0.48; p = 0.032). Significant differences were found between different stages of morphea and total number of blood vessels negative for VEGF, (p = 0.017). In conclusion, VEGF immunostaining, which represents the newly formed blood vessels, showed no difference between lesional and non-lesional skin in patients with morphea. Thus, the dermoscopically observable blood vessels in lesions compared with non-lesional skin are not due to angiogenesis, but rather due to the thinning and atrophy of the overlying epidermis in morphea cases, rendering the blood vessels more obvious.
- 22 January 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (1) , 61-66
Comparison of vascular endothelial growth factor expression between lesional and non-lesional skin in patients with morphea: a dermoscopy-guided immunohistochemical study
Morphea is an inflammatory fibrosing disease, initiated by vascular injury resulting in increased collagen formation and decreased collagen degradation. This study was designed to evaluate the role of angiogenic vascular endothelial growth factor (VEGF) in the vascular changes which are dermoscopically evident in morphea lesions, compared with that in non-lesional skin, by assessing its expression immunohistochemically on tissue blood vessels. Twenty patients with morphea were subjected to clinical and dermoscopic examinations. Two skin biopsies from lesional and non-lesional skin were obtained and stained with hematoxylin and eosin (H&E) and immunohistochemically with VEGF. Dermoscopic examination showed linear blood vessels in 90% of the lesions. No significant difference in the number of VEGF-stained and unstained blood vessels, was observed between the lesional and non-lesional skin (p = 0.475 and 0.191, respectively). A weak inverse correlation was found between the total number of blood vessels positive for VEGF and the disease duration, (r = − 0.48; p = 0.032). Significant differences were found between different stages of morphea and total number of blood vessels negative for VEGF, (p = 0.017). In conclusion, VEGF immunostaining, which represents the newly formed blood vessels, showed no difference between lesional and non-lesional skin in patients with morphea. Thus, the dermoscopically observable blood vessels in lesions compared with non-lesional skin are not due to angiogenesis, but rather due to the thinning and atrophy of the overlying epidermis in morphea cases, rendering the blood vessels more obvious.
- 3 October 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (7) , 3002-3006
Serum and tissue levels of coenzyme Q10 in pemphigus vulgaris
Background: Pemphigus vulgaris (PV) is a debilitating autoimmune blistering disease of the skin and mucous membranes. It occurs due to the action of autoantibodies against various keratinocyte self‐antigens. Anti‐mitochondrial autoantibodies are detected in patients with PV. Coenzyme Q10 (CoQ10) is a member of the mitochondrial respiratory chain involved in cellular metabolism, including apoptosis. This study aimed to assess the serum and tissue levels of CoQ10 of patients with PV and healthy controls to determine its relevance to the disease pathogenesis.Methods: In this case‐control study, 20 patients with PV and 20 healthy controls were included. Blood and skin samples were collected for the measurement of CoQ10 levels using ELISA.Results: CoQ10 was significantly lower in both serum and tissue of patients with PV compared with controls (p = 0.001). Similar results were found when gender subgroups were separately compared. A significant positive correlation was found between serum and tissue CoQ10 levels in controls (p = 0.019, r = 0.521), but not in patients with PV.Conclusion: CoQ10 appears to be one of the parameters affected by the autoimmune response in PV, which may contribute to the tissue damage caused by autoantibodies. The absence of a significant correlation between CoQ10 level and disease severity or duration may be caused by the complex pathophysiological process in PV with multiple autoantibodies against different keratinocyte antigens.
- 3 October 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (7) , 3002-3006
Serum and tissue levels of coenzyme Q10 in pemphigus vulgaris
Background: Pemphigus vulgaris (PV) is a debilitating autoimmune blistering disease of the skin and mucous membranes. It occurs due to the action of autoantibodies against various keratinocyte self‐antigens. Anti‐mitochondrial autoantibodies are detected in patients with PV. Coenzyme Q10 (CoQ10) is a member of the mitochondrial respiratory chain involved in cellular metabolism, including apoptosis. This study aimed to assess the serum and tissue levels of CoQ10 of patients with PV and healthy controls to determine its relevance to the disease pathogenesis.Methods: In this case‐control study, 20 patients with PV and 20 healthy controls were included. Blood and skin samples were collected for the measurement of CoQ10 levels using ELISA.Results: CoQ10 was significantly lower in both serum and tissue of patients with PV compared with controls (p = 0.001). Similar results were found when gender subgroups were separately compared. A significant positive correlation was found between serum and tissue CoQ10 levels in controls (p = 0.019, r = 0.521), but not in patients with PV.Conclusion: CoQ10 appears to be one of the parameters affected by the autoimmune response in PV, which may contribute to the tissue damage caused by autoantibodies. The absence of a significant correlation between CoQ10 level and disease severity or duration may be caused by the complex pathophysiological process in PV with multiple autoantibodies against different keratinocyte antigens.
- 27 September 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (6) , e14349
A randomized study comparing full dose and half dose of rituximab in relapsing pemphigus patients
- 27 September 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (6) , e14349
A randomized study comparing full dose and half dose of rituximab in relapsing pemphigus patients
- 13 September 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (4) , 1298-1302
Serum levels of soluble PD1 in pemphigus vulgaris: A useful marker for disease severity
Background Pemphigus vulgaris (PV) is a life‐threatening autoimmune blistering disease targeting the skin and mucous membranes. Programmed cell death protein 1 (PD1) is an immune checkpoint which binds to two ligands, PDL1 and PDL2 resulting in negative regulation of antigen receptor signaling, thus, play a critical role in the immune regulation of autoimmune diseases. Aim In this work we aimed to assess serum levels of soluble PD1 (sPD1) in patients with active PV and in patients in remission in an attempt to evaluate its effect on disease severity. Methods In this case‐control study, 60 pemphigus vulgaris patients (30 clinically active and 30 in a clinical remission) and 30 age matched healthy control subjects were included. Severity of PV was assessed using pemphigus disease area index (PDAI) score. Serum levels of sPD1 were measured by ELISA for both patients and healthy control. Results Serum levels of sPD1 were significantly lower in PV patients than in controls (P < .001) and significantly lower in patients with active disease than in those in remission (P < .001). Serum sPD1 correlated negatively with the severity of the disease (P < .001, r = −0.4). Conclusion A defect in PD1 pathway is suggested in PV patients, and this defect plays a substantial role in determining the severity of the disease. Thus, sPD1 could be considered a useful marker for disease severity and targeting PD1 pathway could be a potential aim for future therapies of PV.
- 13 September 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (4) , 1298-1302
Serum levels of soluble PD1 in pemphigus vulgaris: A useful marker for disease severity
Background Pemphigus vulgaris (PV) is a life‐threatening autoimmune blistering disease targeting the skin and mucous membranes. Programmed cell death protein 1 (PD1) is an immune checkpoint which binds to two ligands, PDL1 and PDL2 resulting in negative regulation of antigen receptor signaling, thus, play a critical role in the immune regulation of autoimmune diseases. Aim In this work we aimed to assess serum levels of soluble PD1 (sPD1) in patients with active PV and in patients in remission in an attempt to evaluate its effect on disease severity. Methods In this case‐control study, 60 pemphigus vulgaris patients (30 clinically active and 30 in a clinical remission) and 30 age matched healthy control subjects were included. Severity of PV was assessed using pemphigus disease area index (PDAI) score. Serum levels of sPD1 were measured by ELISA for both patients and healthy control. Results Serum levels of sPD1 were significantly lower in PV patients than in controls (P < .001) and significantly lower in patients with active disease than in those in remission (P < .001). Serum sPD1 correlated negatively with the severity of the disease (P < .001, r = −0.4). Conclusion A defect in PD1 pathway is suggested in PV patients, and this defect plays a substantial role in determining the severity of the disease. Thus, sPD1 could be considered a useful marker for disease severity and targeting PD1 pathway could be a potential aim for future therapies of PV.